Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The global recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases. Additionally, steady increase in the number of patients with rare hematological diseases and product approvals by regulatory authorities such as the Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (Japan) are anticipated to drive the market significantly during the forecast period. However, the high cost of treatment and availability of alternative therapies are likely to restrain the global market.
In 2018, the global Recombinant Plasma Protein Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Recombinant Plasma Protein Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recombinant Plasma Protein Therapeutics development in United States, Europe and China.
The key players covered in this study
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Market segment by Type, the product can be split into
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Market segment by Application, split into
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Recombinant Plasma Protein Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Recombinant Plasma Protein Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Recombinant Plasma Protein Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
In 2018, the global Recombinant Plasma Protein Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Recombinant Plasma Protein Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Recombinant Plasma Protein Therapeutics development in United States, Europe and China.
The key players covered in this study
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Market segment by Type, the product can be split into
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others
Market segment by Application, split into
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Recombinant Plasma Protein Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Recombinant Plasma Protein Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Recombinant Plasma Protein Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
